NR293 Pharmacology for Nursing Practice Medication Teaching Plan
NR293 Pharmacology for Nursing Practice Medication Teaching PlanGuidelines
The purpose of this assignment is for the student to synthesize pharmacological knowledge (i.e., core drug knowledge, core patient variables, and nursing implications) of pharmacotherapeutic agents into a useful teaching and learning tool for nurses and patients.
Course outcomes: This assignment enables the student to meet the following course outcomes:
CO1 Apply the concepts of pharmacotherapeutics, pharmacokinetics, pharmacodynamics, and pharmacogenomics to the use of specific medication classifications in specific health conditions and in consideration of medication side/adverse effects, nursing implications, and medication teaching. (POs 1, 2, and 3)
CO2 Apply principles of health promotion, as well as illness and injury prevention, to promote safety and effectiveness of commonly used pharmacologic therapy across the lifespan, taking into consideration sociocultural, genetic/genomic, developmental, and gender implications. (POs 3 and 8)
CO3 Utilize the nursing process in understanding the effects of drug therapy on health outcomes across the lifespan within the framework of a diverse population of individuals, families, and communities. (PO 4)
Due date: Your faculty member will inform you when this assignment is due. The Late Assignment Policy applies to this assignment.
Total points possible: 100 points
Preparing the assignment
Follow these guidelines when completing this assignment. Speak with your faculty member if you have questions.
Choose a pharmacological agent that has been on the market less than 5 years.
Research the literature and obtain two to three resources for current, evidence-based information related to the pharmacological agent.
Brochure for nurses- Focus on nurses for literacy level
•Key/Relevant Drug Information (30 points/30%)
•Patient Education Considerations (35 points/35%)
Developed per the required standard
Graphics enhance the purpose of the brochure
Brochure is visually appealing
•Includes no more than 3 unique errors with APA format (current ed.)
•At least two (2) scholarly, primary sources from the last 5 years, excluding the textbook, are provided
•Includes no more than three unique errors of grammar
•Includes no more than three unique errors in writing mechanics
3.Develop a teaching brochure and one page paper following these guidelines.
oMechanism of Action
oDrug Administration and Dosage
oPatient Education Considerations
oSide Effects/Adverse Effects/Toxicities
oSpecial considerations- provide examples specific to client age needs- geriatric, pediatric and pregnant client
Visual Effects/Creativity (10 points/10%)
oAppropriate for the intended audience
oFlesch-Kincaid reading level seventh grade or lower
b. One Page Paper (15 points/15%)
Describes intended use of brochure
Describe how brochure information would be revised if intended brochure audience had a low health literacy level.
c. APA Format (5 points/5%)
d. Writing and Mechanics (5 points/5%)
Paper is one page, excluding references and title page
For writing assistance, visit the Writing Center.
Please note that your instructor may provide you with additional assessments in any form to determine that youfully understand the concepts learned in the review module.
NR293 Pharmacology for Nursing PracticeMedication Teaching Plan Guidelines
See Rubric Next Page
NR293 Pharmacology for Nursing Practice Medication Teaching Plan
Medication: Rivaroxaban (Brand Name: Xarelto)
Mechanism of Action: Rivaroxaban is an anticoagulant that works by blocking a specific clotting factor in the blood, which helps to prevent blood clots from forming.
Drug Administration and Dosage: Rivaroxaban is available in tablet form, and the recommended dosage may vary depending on the individual’s medical condition. It is important to take the medication exactly as prescribed by the healthcare provider, usually once or twice daily with or without food.
Drug Interactions: Rivaroxaban can interact with other medications, including over-the-counter drugs, herbal supplements, and vitamins. It is important to inform the healthcare provider about all medications currently being taken to avoid potential drug interactions.
Lab effects/interference: Rivaroxaban may affect certain laboratory tests, such as PT/INR and anti-factor Xa assays. It is important to inform the laboratory personnel that you are taking Rivaroxaban before undergoing any laboratory tests.
Special Considerations: Rivaroxaban may increase the risk of bleeding, especially in individuals who are elderly, have a history of bleeding disorders, or are taking other blood-thinning medications. It is important to inform the healthcare provider of any history of bleeding disorders or recent surgeries before starting Rivaroxaban.
Patient Education Considerations:
Take Rivaroxaban exactly as prescribed by the healthcare provider.
Do not stop taking Rivaroxaban without consulting the healthcare provider.
Inform the healthcare provider of any new medications being taken, including over-the-counter drugs, herbal supplements, and vitamins.
Inform the healthcare provider of any signs of bleeding, such as easy bruising, blood in the urine or stool, or excessive bleeding from wounds.
Carry a medical alert card or bracelet indicating that Rivaroxaban is being taken.
Store Rivaroxaban in a cool, dry place, away from children and pets.
Patient Assessment: The healthcare provider will monitor the individual’s medical condition and blood tests to assess the effectiveness of Rivaroxaban and identify any potential side effects or adverse reactions.
Side Effects/Adverse Effects/Toxicities: Common side effects of Rivaroxaban include bleeding, bruising, and gastrointestinal symptoms such as nausea and vomiting. Rare but serious side effects may include severe bleeding, liver damage, and allergic reactions. It is important to inform the healthcare provider of any new or unusual symptoms while taking Rivaroxaban.
Geriatric: Elderly individuals may be at increased risk of bleeding while taking Rivaroxaban.
Pediatric: Rivaroxaban is not recommended for use in children.
Pregnant client: Rivaroxaban may be harmful to a developing fetus and is not recommended during pregnancy.
Visual Effects/Creativity: The teaching brochure will include graphics and images that enhance the purpose of the brochure and make it visually appealing. The brochure will be appropriate for the intended audience and have a Flesch-Kincaid reading level of seventh grade or lower.
One Page Paper:
The intended use of the brochure is to provide information about Rivaroxaban to healthcare providers and patients, including key drug information, patient education considerations, nursing management, and special considerations for different client age needs.
If the intended brochure audience had a low health literacy level, the information would be revised to use simple language and visual aids to enhance understanding. The brochure would also be reviewed by individuals with low health literacy to ensure that the information is easy to understand.
APA Format: The brochure and one-page paper will adhere to current APA format guidelines.
Writing and Mechanics: The brochure and one-page paper will